Pharmaceutical companies should consider what is required for QIDP designation and whether they can use it to extend the protection afforded to their innovative products.
Glen C. Cheng, MD
Advertisement
Glen C. Cheng, MD, Regulatory Counsel, Office of Regulatory Policy, Center for Drug Evaluation and Research, FDA.
Articles by Glen C. Cheng, MD
Advertisement
Latest Updated Articles
- Time to GAIN: Are Your FDA Marketing Exclusivities Eligible for Extension?
Published: May 7th 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
2
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
3
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
4
PharmTech Weekly News Roundup – Week of November 3, 2025
5
